Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer.

@article{Mathieu2010ComparisonOF,
  title={Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer.},
  author={Anne Mathieu and Birgit Weynand and Eric Verbeken and Susana Da Silva and Christine Decaestecker and Isabelle Salmon and Pieter Demetter},
  journal={Lung cancer},
  year={2010},
  volume={69 1},
  pages={46-50}
}
Agents acting on signalling molecules of growth pathways have emerged as therapeutics for non-small cell lung cancer (NSCLC). Among them are inhibitors of the epidermal growth factor receptor (EGFR). To meet Belgian reimbursement criteria for erlotinib, patients must have an EGFR-positive tumour, defined as at least 10% of cells showing membranous staining on immunohistochemistry. This study compares results obtained with the Dako pharmDx kit versus other anti-EGFR antibodies in 634 NSCLC. More… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Similar Papers

Loading similar papers…